| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
105,890,000 |
| Market
Cap: |
896.89(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$6.87 - $18.44 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 20.4 |
| Insider 3/6 Months : 21 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating cancer therapies. Co.'s products include: Domvanalimab, which is an anti-TIGIT monoclonal antibody designed to promote sustained immune activation and tumor clearance; Etrumadenant, which is a dual A2a/A2b adenosine receptor antagonist, designed to inhibit the adenosine-driven impairment of tumor-infiltrating lymphocytes and myeloid cells; AB680, which is a potent and selective small-molecule CD73 inhibitor designed to provide differential benefits relative to monoclonal antibodies; and Zimberelimab, which is Co.'s anti-PD-1 antibody that Co. in-licensed to enable the development of its combination regimens.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
1,403,436 |
1,403,436 |
16,641,531 |
| Total Buy Value |
$0 |
$15,402,661 |
$15,402,661 |
$335,402,656 |
| Total People Bought |
0 |
3 |
3 |
3 |
| Total Buy Transactions |
0 |
3 |
3 |
4 |
| Total Shares Sold |
0 |
0 |
5,152 |
212,960 |
| Total Sell Value |
$0 |
$0 |
$77,303 |
$4,147,171 |
| Total People Sold |
0 |
0 |
2 |
4 |
| Total Sell Transactions |
0 |
0 |
3 |
15 |
| End Date |
2025-04-06 |
2025-01-03 |
2024-07-05 |
2023-07-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Rosen Terry J |
Chief Executive Officer |
• • – |
2021-06-17 |
4 |
S |
$23.68 |
$115,156 |
D/D |
(4,863) |
205,562 |
|
- |
|
| Jaen Juan C. |
President |
• • – |
2021-06-17 |
4 |
S |
$23.68 |
$63,344 |
D/D |
(2,675) |
198,286 |
|
- |
|
| Tang Carolyn C. |
General Counsel |
• – – |
2021-06-17 |
4 |
S |
$23.68 |
$38,030 |
D/D |
(1,606) |
15,362 |
|
- |
|
| Jarrett Jennifer |
Chief Operating Officer |
• • – |
2021-06-17 |
4 |
S |
$23.68 |
$115,156 |
D/D |
(4,863) |
135,343 |
|
- |
|
| Grossman William |
Chief Medical Officer |
• – – |
2021-06-17 |
4 |
S |
$23.68 |
$92,139 |
D/D |
(3,891) |
20,723 |
|
- |
|
| Rosen Terry J |
Chief Executive Officer |
• • – |
2021-06-16 |
4 |
S |
$24.13 |
$95,850 |
D/D |
(3,968) |
210,425 |
|
- |
|
| Jaen Juan C. |
President |
• • – |
2021-06-16 |
4 |
S |
$24.13 |
$52,707 |
D/D |
(2,182) |
200,961 |
|
- |
|
| Tang Carolyn C. |
General Counsel |
• – – |
2021-06-16 |
4 |
S |
$24.13 |
$31,619 |
D/D |
(1,309) |
16,968 |
|
- |
|
| Jarrett Jennifer |
Chief Operating Officer |
• • – |
2021-06-16 |
4 |
S |
$24.13 |
$95,850 |
D/D |
(3,968) |
140,206 |
|
- |
|
| Grossman William |
Chief Medical Officer |
• – – |
2021-06-16 |
4 |
S |
$24.13 |
$76,670 |
D/D |
(3,174) |
24,614 |
|
- |
|
| Jarrett Jennifer |
Chief Operating Officer |
• • – |
2021-06-04 |
4 |
S |
$24.91 |
$26,006 |
D/D |
(1,044) |
119,174 |
|
- |
|
| Falberg Kathryn E |
Director |
– • – |
2021-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
86,504 |
|
- |
|
| Kaneko Yasunori |
Director |
– • – |
2021-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
6,000 |
|
- |
|
| Lacey David L. |
Director |
– • – |
2021-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
38,352 |
|
- |
|
| Perlman Andrew J |
Director |
– • – |
2021-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
5,525 |
|
- |
|
| Ribas Antoni |
Director |
– • – |
2021-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
11,050 |
|
- |
|
| Machado Clarence Patrick |
Director |
– • – |
2021-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
6,000 |
|
- |
|
| Kaneko Yasunori |
Director |
– • – |
2021-04-23 |
4 |
B |
$31.37 |
$129,652 |
D/D |
4,133 |
7,133 |
2.39 |
- |
|
| Grossman William |
Chief Medical Officer |
• – – |
2021-04-23 |
4 |
S |
$31.37 |
$129,652 |
D/D |
(4,133) |
6,717 |
|
- |
|
| Falberg Kathryn E |
Director |
– • – |
2021-03-31 |
4 |
B |
$28.35 |
$566,996 |
I/I |
20,000 |
102,106 |
2.1 |
- |
|
| Jarrett Jennifer |
Chief Operating Officer |
• • – |
2021-03-16 |
4 |
S |
$35.03 |
$303,394 |
D/D |
(8,661) |
116,973 |
|
- |
|
| Grossman William |
Chief Medical Officer |
• – – |
2021-03-16 |
4 |
S |
$35.03 |
$74,509 |
D/D |
(2,127) |
10,850 |
|
- |
|
| Rosen Terry J |
Chief Executive Officer |
• • – |
2021-02-01 |
4 |
GD |
$0.00 |
$0 |
I/I |
311,900 |
0 |
|
- |
|
| Gilead Sciences Inc |
10% Owner |
– – • |
2021-01-31 |
4 |
B |
$39.00 |
$220,350,000 |
D/D |
5,650,000 |
13,913,029 |
2.45 |
- |
|
| Rosen Terry J |
Chief Executive Officer |
• • – |
2021-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
45,000 |
234,393 |
|
- |
|
56 Records found
|
|
Page 1 of 3 |
|
|
0.12 (1.4%) 
